Glucose Viaflo Baxter Médico Farmacêutica

Glucose Viaflo Baxter Médico Farmacêutica is an intravenous solution containing glucose monohydrate as the active ingredient. It is supplied in a sterile liquid form for parenteral administration, typically without a specified concentration, and is marketed in the European Union as a prescription‑only product. The preparation is intended for use in clinical settings where delivery of carbohydrate calories and fluid balance is required, such as hospitals, care units, and emergency departments.

Glucose Viaflo is employed when an immediate source of glucose is needed to correct low blood sugar or to support fluid and electrolyte therapy in patients who cannot receive nutrition orally, or to provide an energy substrate during intravenous fluid therapy.

- Treatment of hypoglycemia in acute care. - Component of parenteral nutrition regimens. - Fluid and electrolyte replacement during surgery or trauma. - Maintenance of blood glucose levels in critically ill patients. - Support for metabolic needs during prolonged fasting. - Rehydration in patients with combined glucose and fluid deficits. - Adjunct in drug dilution for compatible intravenous medications.

When administered intravenously, Glucose Viaflo may be associated with a range of adverse reactions, most of which are mild and transient, while rare serious events can occur under certain conditions.

Common: - Mild hyperglycemia or transient rise in blood glucose. - Local irritation or pain at the infusion site. - Nausea or vomiting related to rapid glucose infusion. - Electrolyte shifts such as mild hypokalemia.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic reactions including rash, urticaria, or anaphylaxis. - Volume overload in patients with compromised cardiac function.

Clinicians should evaluate patient-specific factors before using Glucose Viaflo to minimize risks and ensure appropriate therapeutic benefit.

- Assess blood glucose levels and adjust infusion rate accordingly. - Monitor electrolytes, especially potassium and sodium, during and after infusion. - Use caution in patients with renal impairment or fluid overload risk. - Avoid rapid infusion in neonates and infants to prevent metabolic disturbances. - Review compatibility with other intravenous solutions before co‑administration. - Consider cardiac status in patients with heart failure or coronary disease.

Glucose Viaflo can interact with other intravenous agents or systemic medications, influencing glucose balance or fluid status.

Avoid: - Concurrent administration with high‑dose insulin without close glucose monitoring. - Mixing with solutions containing calcium or phosphate that may precipitate.

Use with caution: - Concurrent use of diuretics that affect electrolyte balance. - Co‑administration with beta‑adrenergic agonists that can raise blood glucose. - Use alongside total parenteral nutrition formulations to avoid excess caloric load.